Biological Markers and Advanced Imaging for Prostate Cancer Progression in Active Surveillance

Inclusion Criteria

• •Histologically proven low-risk PCa (PSA ≤10 ng/ml; clinical stage ≤T2a, and biopsy ISUP GG 1)
• •Non-metastatic status at study inclusion (patient enrollment).
• •No prior or concomitant androgen deprivation therapy
• •Ability to understand a written informed consent and willingness to sign it.